Cite
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
MLA
Diener, Hans Christoph, et al. “Safety and Tolerability of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies.” Cephalalgia, vol. 42, no. 8, July 2022, pp. 769–80. EBSCOhost, https://doi.org/10.1177/03331024221076485.
APA
Diener, H. C., McAllister, P., Jürgens, T. P., Kessler, Y., Ning, X., Cohen, J. M., Campos, V. R., Barash, S., & Silberstein, S. D. (2022). Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. Cephalalgia, 42(8), 769–780. https://doi.org/10.1177/03331024221076485
Chicago
Diener, Hans Christoph, Peter McAllister, Tim P Jürgens, Yoel Kessler, Xiaoping Ning, Joshua M Cohen, Verena Ramirez Campos, Steve Barash, and Stephen D Silberstein. 2022. “Safety and Tolerability of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies.” Cephalalgia 42 (8): 769–80. doi:10.1177/03331024221076485.